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Abstract
Toll like receptors (TLRs) are important pattern recognition receptors that can detect patho-
gen and danger associated molecular patterns to initiate an innate immune response. TLR1
and 2 heterodimerize at the plasma membrane upon binding to triacylated lipopeptides from
bacterial cell walls, or to the synthetic ligand Pam3CSK4. TLR1/2 dimers interact with adap-
tor molecules TIRAP and MyD88 to initiate a signalling cascade that leads to activation of
key transcription factors, including NF-kB. Despite TLRs being extensively studied over the
last two decades, the real-time kinetics of ligand binding and receptor activation remains
largely unexplored. We aimed to study the kinetics of TLR activation and recruitment of adap-
tors, using TLR1/2 dimer interactions with adaptors MyD88 and TIRAP. Bioluminescence
resonance energy transfer (BRET) allows detection of real-time protein-protein interactions
in living cells, and was applied to study adaptor recruitment to TLRs. Energy transfer showed
interactions between TLR2 and TIRAP, and between TLR2 and MyD88 only in the presence
of TIRAP. Quantitative BRET and confocal microscopy confirmed that TIRAP is necessary
for MyD88 interaction with TLR2. Furthermore, constitutive proximity between the proteins in
the absence of Pam3CSK4 stimulation was observed with BRET, and was not abrogated
with lowered protein expression, changes in protein tagging strategies, or use of the brighter
NanoLuc luciferase. However, co-immunoprecipitation studies did not demonstrate constitu-
tive interaction between these proteins, suggesting that the interaction observed with BRET
likely represents artefacts of protein overexpression. Thus, caution should be taken when uti-
lizing protein overexpression in BRET studies and in investigations of the TLR pathway.
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Introduction
The main mechanism by which innate immune cells detect foreign pathogens is through
pattern recognition receptors. These receptors recognise danger- or pathogen-associated
molecular patterns (DAMPs or PAMPs), which are normally absent in the healthy host. Rec-
ognition initiates a signalling cascade that stimulates the cell to respond through both inflam-
matory cytokine release and cellular activation to mediate pathogen destruction. Toll-like
receptors (TLRs) are a well characterized group of pattern recognition receptors that play a
crucial role in the initial detection of pathogens by the innate immune system [1, 2]. TLRs are
transmembrane glycoproteins with a ligand-binding domain in the extracellular N-terminus,
and a downstream signalling domain in the intracellular C-terminus. These receptors are pro-
posed to dimerize upon ligand binding, wherein the C-terminal regions of the receptors are
brought into contact, and activate signalling through interaction with adaptor proteins [3, 4].
The signal transduction from TLRs to their binding partners occurs via the Toll-interleukin-1
receptor (TIR) domain, which is present in both TLRs and adaptors [2]. TLRs activate
downstream signalling cascades that lead to activation of transcription factors, such as
nuclear factor kappa light-chain enhancer of activated B cells (NF-κB), activator protein-1
(AP-1), and interferon regulatory factors (IRFs), which in turn initiate a pro-inflammatory
response [4].
Humans encode ten TLRs, which detect different PAMPs and DAMPs. TLR2 heterodi-
merizes with TLR1 or TLR6 to detect triacyl or diacyl lipopeptides, respectively [3, 5]. These
receptors are essential for immune responses to Gram-positive and Gram-negative bacteria,
and are also involved in detection of PAMPs from fungi and parasites like Plasmodium and
Trypanosoma cruzi. All TLRs, with the exception of TLR3, signal through adaptor Myeloid
differentiation factor 88 (MyD88). Additionally, both MyD88 and TIR domain containing
adaptor protein (TIRAP, MAL) are necessary for signal transduction from TLR2 and TLR4
[4, 6]. TIRAP directly interacts with MyD88 [7, 8], and contains a phosphatidylinositol
4,5-bisphosphate (PIP2) binding site that localizes it to the plasma membrane [9]. TIRAP
therefore serves as a bridging adaptor between MyD88 and TLR2, recruiting MyD88 to the
plasma membrane where it can be activated by concomitant TLRs. Upon receptor activation,
MyD88 is recruited and subsequently interacts with members of the IL-1R-associated kinase
(IRAK) family via its death domain [10, 11], to form a multimeric signalling platform called
the Myddosome [12]. This in turn triggers downstream signalling that results in NF-κB acti-
vation [6].
Due to their central role in pathogen detection, TLRs are targets of pathogen inhibition in
order to avoid detection. There are numerous examples of viral and bacterial proteins that
inhibit TLR signalling [13–16]. These can target in particular the interaction between TLRs
and adaptor molecules. Furthermore, overstimulation of immune responses can also be detri-
mental to the host. DAMPs released by damaged cells can stimulate TLRs and initiate a posi-
tive feedback loop to cause excessive inflammation. TLRs are increasingly being associated
with inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and
atherosclerosis [17, 18]. Thus, the development of therapies that specifically target the interac-
tion between TLRs and adaptors to modulate signalling could have important therapeutic
applications. However, previous studies of TLR-adaptor interactions and of pathogen TLR-
modulating proteins have investigated activation of more general downstream pathways, such
as NF-κB activation, mitogen activated protein kinase (MAPK) activity, and cytokine secretion
[6, 19, 20]. Since several extracellular stimuli and/or surface receptors converge on these down-
stream pathways, it is difficult to dissect the exact interaction that is causing the measured
effect. A more specific and sensitive method to monitor the interactions between TLRs and
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adaptors could provide a better understanding of potency of ligand binding, and allow the
investigation of molecules that specifically affect the interactions between TLRs and adaptor
molecules.
Bioluminescence resonance energy transfer (BRET) is a technique for real-time monitoring
of protein-protein interactions in live cells. It has been extensively used to study G protein-
coupled receptors [21–23], but to our knowledge has never been adapted for use with TLRs. In
BRET, proteins of interest are tagged with either a luciferase enzyme or a fluorophore, and
expressed in target cells. Upon treatment with the luciferase substrate, light is emitted from the
luciferase at a specific wavelength. If the ‘donor’ luciferase-tagged protein comes within close
proximity to the ‘acceptor’ fluorophore-tagged protein, less light is emitted from the luciferase
and resonance energy transfer excites the fluorophore, resulting in light emission from the
fluorophore at a different wavelength. Energy transfer is indicative of direct interactions
between the tagged proteins, as it only occurs when the proteins are within about 8 nm of each
other [24]. Therefore, BRET has the potential to allow specific and sensitive detection of the
interactions between TLRs and adaptor proteins. We aimed to apply BRET to study the kinet-
ics of TLR and adaptor interaction in live cells, using TLR1/2 binding to TIRAP and MyD88 as
a model system.
Results
Tagged TLR1/2 and TIRAP, but not MyD88, localize to the plasma
membrane
In order to investigate the real-time kinetics of TLR1/2 activation in live cells by BRET,
TLR1 was left untagged, TLR2 was tagged with donor luciferase (Rluc8), and TIRAP or
MyD88 was tagged with the acceptor fluorophore (Venus). This combination of luciferase
and fluorophore has been previously demonstrated to perform well in BRET experiments
[25]. Western blot analysis of HEK293FT cells transfected with these DNA expression con-
structs showed that the tagged proteins were co-expressed in a dose-dependent manner and
at the expected molecular weight (Fig 1A–1D). Confocal microscopy of cells transfected with
MyD88-Venus or TIRAP-Venus constructs showed that TIRAP-Venus localized mostly to
the plasma membrane, as was expected (Fig 1E), whereas MyD88 was found in condensed
intracellular structures (Fig 1F), consistent with that previously reported for overexpressed
MyD88 [9, 26–28].
In order to determine if TLR2 was localized to the plasma membrane upon expression in
cells, TLR1 and TLR2-Rluc8 constructs were co-transfected with Kras-Venus construct and
BRET was measured. Kras-Venus contains only the C-terminal fragment of Kras N-terminally
linked to Venus, and when overexpressed in cells, it coats the plasma membrane with Venus
fluorophore to function as a plasma membrane ‘tag’ for BRET [29]. The BRET ratio is deter-
mined by dividing light emission at wavelengths characteristic of the fluorophore’s emission
peak by light emission characteristic of the luciferase’s emission peak. When TLR1/2-Rluc8
was co-transfected with Kras-Venus, a significant increase in BRET ratio was observed (1.33)
compared to TLR1/2-Rluc8 only (0.25), indicating the receptors were plasma membrane-local-
ized (Fig 1G). Indeed, the BRET ratio was significantly greater than that observed with Vaso-
pressin-2-receptor (V2R)-Rluc8, a plasma membrane-localized GPCR previously assessed
using BRET [22] that was used as a positive control. Thus, tagged TLR2, MyD88, and TIRAP
were successfully ectopically expressed in HEK293FT cells, and displayed the expected subcel-
lular localization.
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Fig 1. BRET constructs are functional and appear to be appropriately localized when transfected into cells. A-D) HEK293FT cells were
transfected with 0, 30 or 300 ng of TLR1, TLR2-Rluc8, TIRAP-Venus or MyD88-Venus constructs, alone or in combination, and analysed
for protein expression by Western immunoblot (IB) as indicated, along with lysate from untransfected THP1 cells. HEK293FT cells were
transfected with E) TIRAP-Venus or F) MyD88-Venus constructs, DAPI stained, and imaged by confocal microscopy. Yellow = Venus,
blue = nucleus; representative images of two independent experiments. G) HEK293FT cells were transfected with 100 ng TLR1/2-Rluc8
construct only (negative control), 100 ng TLR1/2-Rluc8 + 100 ng Kras-Venus constructs, and 100 ng V2R-Rluc8 + 100 ng Kras-Venus
constructs (positive control) and BRET ratio was measured. Error bars represent SD of three independent experiments. One-way ANOVA;
 = P<0.0001,  = P<0.01.
https://doi.org/10.1371/journal.pone.0202408.g001
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BRET shows ligand-independent interaction between TLR1/2 and adaptors
TLR1/2-Rluc8 co-expression with TIRAP-Venus or MyD88-Venus caused an increase in
BRET ratio, when compared to TLR1/2-Rluc8 alone (Fig 2A). Note that background BRET
ratio is caused by luminescence detection in the ‘fluorescence’ channel, and has been sub-
tracted from all subsequent BRET graphs. When BRET ratios with MyD88-Venus and TIR-
AP-Venus were compared (Fig 2B), MyD88-Venus was found to result in a significantly lower
BRET ratio than TIRAP-Venus. However, if untagged TIRAP was co-expressed with MyD88-
Venus, BRET increased to levels equivalent to that of TIRAP-Venus (Fig 2B). Co-expression of
untagged MyD88 with TIRAP-Venus had no effect on TIRAP interaction with the receptors.
These data are consistent with current knowledge that TIRAP serves as a bridging adaptor for
MyD88, and is required for MyD88 interaction with TLRs [8, 9].
Ligand-induced BRET is defined as a change in BRET ratio after addition of a specific
ligand, and is used to demonstrate changes in proximity between two proteins as a result of
stimulation by the ligand [30]. Cells were transfected with TLR1/2-Rluc8 and either TIRAP-
Venus (Fig 2C), or MyD88-Venus and untagged TIRAP constructs (Fig 2D). Pam3CSK4 is a
synthetic triacyl lipopeptide and a well-characterized specific ligand for TLR1/2. Addition of
Pam3CSK4 to transfected cells was expected to activate the TLR1/2 and induce interaction
with TIRAP and MyD88, causing an increase in BRET ratio [5]. However, there was no change
in BRET ratio after Pam3CSK4 treatment of cells transfected with either TLR1/2 + TIRAP-Ve-
nus (Fig 2C) or TLR1/2 + MyD88-Venus + TIRAP constructs (Fig 2D). Despite very high
Pam3CSK4 concentrations being used (10 μg/ml), the BRET ratio was the same as vehicle-
only control. Pam3CSK4 was confirmed to be biologically active, as it induced TNF cytokine
responses in THP1 cells, a human monocytic cell line. Pam3CSK4 did not induce a TNF
response from HEK293FT cells, with or without TLR pathway transfection, likely due to
absence of a functional pathway for TNF expression (Fig 2E).
BRET indicates constitutive proximity between overexpressed proteins
Although no ligand-induced BRET was detected, the high ‘resting’ BRET ratio between TLR1/
2-Rluc8 and TIRAP-Venus, and between TLR1/2-Rluc8 and MyD88-Venus in the presence of
TIRAP, suggested a constitutive interaction between these proteins. This was unexpected, as it
has been generally assumed that TIRAP and MyD88 only interact with TLRs upon ligand
binding and receptor activation. To provide further evidence for constitutive TIRAP proximity
with TLR1/2, the BRET saturation assay was employed. Increasing concentrations of fluoro-
phore-tagged constructs were transfected, whilst the concentration of luciferase-tagged con-
struct was kept constant [31]. The BRET signal was then plotted as a function of acceptor/
donor expression ratio. Specific proximity theoretically results in a saturation curve, compared
to a linear or quasi-linear relationship due to random co-localization [31]. These curves can be
determined using nonlinear regression model fitting (GraphPad Prism, one site—specific
binding). From the saturation BRET curve, a BRET50 value can be calculated, which is the fluo-
rescence/luminescence value at 50% of the maximal BRET signal. It has been suggested that a
low BRET50 is indicative of a direct interaction, whereas a higher BRET50 indicates weak or no
interaction [32].
BRET between TLR1/2-Rluc8 and TIRAP-Venus showed clear saturation, supportive of
constitutive proximity between these two proteins (Fig 3A, blue curve). This specificity
was further demonstrated by a low BRET50 value of 0.117 (Table 1). In contrast, BRET
between TLR1/2-Rluc8 and MyD88-Venus had a linear relationship indicating a clear lack of
proximity (Fig 3A, red line). This was consistent with confocal microscopy experiments (Fig
1F), which demonstrated that in the absence of TIRAP, overexpressed MyD88 was localized
BRET analysis of TLR-adaptor interactions is hampered by protein overexpression
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Fig 2. TIRAP directly interacts with TLR1/2, but does not show ligand-induced BRET increase. A) HEK293FT cells were transfected with
100 ng TLR1 and 100 ng TLR2-Rluc8 constructs, and additionally with 300 ng MyD88-Venus, or 300 ng TIRAP-Venus constructs, and BRET
measured over time. Graph shown is representative of three independent experiments; error bars represent SD of triplicate wells. B)
Transfections as in (A), with additional cells transfected with 300 ng MyD88-Venus + 300 ng TIRAP constructs, or 300 ng MyD88 + 300 ng
TIRAP-Venus constructs. Data shown as % of max BRET, where max is TLR1/2-Rluc8 + TIRAP-Venus; n = 4 independent experiments. One-
way ANOVA;  = P<0.0001. HEK293FT cells transfected with 300 ng TLR1 + 300 ng TLR2-Rluc8 constructs and additionally with either C)
300 ng TIRAP-Venus or D) 100 ng MyD88-Venus + 300 ng of TIRAP constructs. Cells were stimulated with 10 μg/ml Pam3CSK4 or vehicle
control and BRET measured over time. Data shown are donor-only-subtracted BRET ratio; graphs are representative of three independent
experiments. E) Untransfected THP1 cells, or HEK293FT cells transfected with 0 or 300 ng of TLR1/2, MyD88 and TIRAP constructs (TLR
pathway), were treated with increasing concentrations of Pam3CSK4, as indicated, and TNF was measured in culture medium after 24 hr. Dose-
response curve was fitted using Graphpad Prism non-linear fit with variable slope (EC50 = 14.4 for THP1 cells).
https://doi.org/10.1371/journal.pone.0202408.g002
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intracellularly away from the plasma membrane. In contrast, when untagged TIRAP was co-
expressed with MyD88-Venus, clear saturation was observed, demonstrating again that
MyD88 requires TIRAP to interact with TLR1/2 (Fig 3A, black curve). V2R-Venus was used as
a negative control, as this receptor was not expected to specifically interact with TLR1/2.
Fig 3. When overexpressed, TIRAP constitutively interacts with TLR1/2 but MyD88 interaction only occurs in the presence of TIRAP. A)
HEK293FT cells were transfected with constant (100 ng) TLR1/2-Rluc8 and increasing (0–1000 ng) TIRAP-Venus (blue circles; combined
n = 7), MyD88-Venus (red triangles; combined n = 3), MyD88-Venus + TIRAP (black squares, combined n = 2), or V2R-Venus constructs
(green inverted triangles, combined n = 3). B) HEK293 cells were transfected with constant (50 ng) TLR1/2-Rluc8 and increasing (0–1000 ng)
MyD88-Venus + TIRAP constructs at the concentrations indicated (combined n = 2). Saturation curves were fitted using ‘one site—specific
binding’ function on Prism software. Data shown are combined from independent experiments, as indicated. C) HEK293FT cells were
transfected with Venus-tagged and untagged MyD88 and TIRAP constructs as indicated, DAPI stained, and imaged by confocal microscopy.
Yellow = Venus, blue = nucleus; representative images of two independent experiments.
https://doi.org/10.1371/journal.pone.0202408.g003
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Intriguingly, a saturation curve for TLR1/2-Rluc8 and V2R-Venus was observed, although this
was lower than that of TLR1/2 and TIRAP (Fig 3A, green curve). The BRET50 value was also
higher for TLR1/2-Rluc8 and V2R-Venus (0.193), which are not known to have any meaning-
ful biological interactions. This effect with saturation BRET can occur with overexpression of
proteins that might co-localize at the cell membrane without any functional consequences
[33], and again illustrates the need for careful interpretation of saturation BRET data. This
being said, the clear linear relationship for TLR1/2-Rluc8 + MyD88-Venus with the switch to a
clear saturation curve upon co-expression of TIRAP illustrates the utility of this approach
under certain circumstances.
To further investigate the role of TIRAP in bridging MyD88 and TLR1/2, BRET saturation
assays were performed as before, with constant TLR1/2-Rluc8 and TIRAP constructs co-trans-
fected with increasing MyD88-Venus construct. Multiple individual curves were generated,
each with different amounts of constant TIRAP DNA construct transfection. As TIRAP con-
struct concentrations increased, the linear relationship changed to a saturation curve, indicat-
ing that a minimum expression level of TIRAP was required to allow constitutive interaction
of MyD88 with TLR1/2 (Fig 3B). Weak interactions between TLR1/2-Rluc8 and MyD88-Ve-
nus, in the absence of TIRAP, were highlighted by an incalculable BRET50 value (Table 1).
However, when TIRAP was co-transfected with MyD88-Venus in increasing DNA construct
concentrations, the calculable BRET50 value decreased (Table 1). This indicated specific prox-
imity when more than 10 ng of TIRAP construct was transfected. The saturation BRET results
suggest that a threshold amount of TIRAP is needed to allow MyD88 to interact with TLR1/2.
Indeed, when MyD88-Venus construct was co-transfected with untagged TIRAP construct at
equal concentrations, there was no effect on MyD88 localization seen by confocal microscopy,
but when TIRAP construct was transfected at three-fold higher concentration, MyD88 locali-
zation changed to small punctate staining at or near the plasma membrane (Fig 3C). In
Table 1. BRET50 values calculated from BRET saturation curves show MyD88 and TLR2 interactions are dependent on TIRAP concentration.
BRET50 BRET50 SEM BRETmax BRETmax SEM
TLR-Rluc8 +
TIRAP-Venus
0.117 0.011 0.23 0.004
TLR-Rluc8 +
V2R-Venus
0.193 0.022 0.16 0.005
TLR-Rluc8 + MyD88-Venus + TIRAP
TIRAP (ng DNA)
0 ND ND ND ND
10 ND ND ND ND
20 0.71 0.063 0.21 0.0076
50 0.43 0.081 0.23 0.014
100 0.29 0.038 0.23 0.0087
200 0.27 0.018 0.26 0.0041
400 0.19 0.014 0.24 0.0041
600 0.090 0.0097 0.21 0.0044
800 0.066 0.022 0.20 0.0070
SEM—standard error
BRETmax—maximum BRET ratio, calculated from the fitted curve
BRET50—fluorescence/luminescence value at 50% BRETmax, calculated as the equilibrium binding constant (Kd) from the fitted curve
 Curves for 0 and 10 ng TIRAP DNA constructs are sufficiently linear that curves cannot be fitted with enough accuracy to determine appropriate BRETmax and
BRET50 values.
https://doi.org/10.1371/journal.pone.0202408.t001
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contrast, co-transfection of MyD88 construct had no effect on TIRAP localization (Fig 3C).
Thus, confocal microscopy confirms that a threshold amount of TIRAP is necessary to redis-
tribute MyD88.
NanoBRET allows investigation with lower protein expression, but
constitutive proximity is still observed
The constitutive proximity between TLR1/2, TIRAP and MyD88 seen in the BRET experi-
ments in the absence of ligand was unexpected, as previous work indicated that MyD88 only
interacts with TIRAP upon ligand stimulation [34]. However, it was also shown that overex-
pression of MyD88 induced constitutive NF-κB activation [35] and ligand-independent inter-
action between TLR4 and MyD88 [36]. Indeed, co-transfection of the TLR pathway proteins
with a firefly luciferase (Fluc) NF-κB reporter construct showed an NF-κB response that was
dose dependent on the TLR pathway components, but was independent of Pam3CSK4 (Fig
4A–4C). Therefore, the constitutive interaction between TLR1/2, TIRAP and MyD88 observed
with BRET might be due to overexpression of these proteins, resulting in spontaneous interac-
tion/oligomerization.
Overexpression of tagged constructs tends to be necessary when performing BRET with
Rluc8 and Venus, because bright luminescent signals are required for detection. However,
Nanoluc (Nluc), a new luciferase enzyme that is significantly brighter than Rluc8, was recently
applied to BRET studies [37]. Use of Nluc can lower the limit of detection for BRET, essentially
allowing sensitive BRET measurement with reduced expression levels of the enzyme (termed
NanoBRET). In an attempt to overcome the potentially non-specific constitutive interactions
between TLR1/2, MyD88 and TIRAP due to protein overexpression, the BRET assay was
repeated using Nluc in place of Rluc8.
NanoBRET using TLR1/2-Nluc and MyD88-Venus or TIRAP-Venus allowed a 10-fold
reduction in construct expression whilst still providing detectable BRET signal. Cells trans-
fected with 5 ng of TLR2-Nluc construct (Fig 4E) allowed for a stably detectable BRET signal
compared to cells transfected with 50 ng of TLR2-Nluc construct (Fig 4D). Due to the brighter
light emission of Nluc compared to Rluc8 [37], lower DNA construct concentrations were
used for transfection in order to prevent signal saturation. However, ligand-induced BRET
remained undetectable, since treatment with Pam3CSK4 did not induce a change in BRET
ratio compared to vehicle only control (Fig 4D and 4E). Therefore, simply exchanging Rluc8
for Nluc in this experimental setup was not sufficient to improve measurement of ligand-
induced receptor-adaptor protein interactions.
Since the current understanding is that TIRAP and MyD88 should only interact upon
ligand activation of a receptor, the monitoring of interactions between these two proteins
was attempted as a strategy for assessing ligand-induced BRET. MyD88, which based on previ-
ous experiments seemed to be most prone to oligomerization, was tagged with Nluc to allow
lowest possible expression levels. Cells were co-transfected with MyD88-Nluc and TIRAP-Ve-
nus construct along with untagged TLR1/2 construct, and the BRET ratio was measured in
response to Pam3CSK4 ligand or vehicle only control. Stimulation of TLR1/2 with Pam3CSK4
was expected to induce interaction between MyD88-Nluc and TIRAP-Venus, however, no
change in BRET was observed (Fig 4F). Despite the concentration of transfected DNA con-
struct being reduced ten-fold, constitutive BRET was still apparent between MyD88-Nluc and
TIRAP-Venus, indicated by a saturation BRET curve (Fig 4G). Therefore, it appears that con-
stitutive proximity between MyD88 and TIRAP still occurred when these proteins were over-
expressed in cells, even if low transfection concentrations of DNA construct were used. In fact,
BRET analysis of TLR-adaptor interactions is hampered by protein overexpression
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Fig 4. Modified BRET using Nluc allowed reduction in protein expression levels, but did not enable observation
of ligand-induced BRET ratio. A) HEK293FT cells were transfected with 100 ng of TLR1/2, MyD88 and TIRAP
constructs (TLR pathway) and 0, 100, 200 or 400 ng of NF-κB luciferase constructs, and treated with 1 μg/ml
Pam3CSK4. NF-κB luciferase levels measured after 24 hr; representative experiment of n = 3. B and C) HEK293FT
cells were transfected with 200 ng of NF-κB-Fluc constructs and 0, 25, 50 or 100 ng of TLR1/2, MyD88 and TIRAP
constructs (TLR pathway), and treated with 1 μg/ml Pam3CSK4. NF-κB reporter Fluc luciferase (B) and TLR-Rluc8
luciferase (C) levels measured after 24 hr; representative experiment of n = 2. HEK293FT cells transfected with D) 50
ng TLR1 + 50 ng TLR2-Nluc + 50 ng MyD88-Venus + 100 ng TIRAP constructs, or E) 5 ng TLR1 + 5 ng TLR2-
Nluc + 5 ng MyD88-Venus + 10 ng TIRAP constructs. Cells were stimulated with 1 μg/ml Pam3CSK4 (red) or vehicle
BRET analysis of TLR-adaptor interactions is hampered by protein overexpression
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transfection of TIRAP-Venus and MyD88-Venus constructs, even at the low concentrations
used in NanoBRET, still produced overexpression of these proteins in HEK293FT cells (Fig
5A). These remained significantly higher than the endogenous protein levels in human pri-
mary dendritic cells.
control (blue) and BRET measured over time. Data shown are donor-only-subtracted BRET ratio; graphs are
representative of three independent experiments. F) HEK293FT cells were transfected with 100 ng TLR1 + 100 ng
TLR2 + 10 ng MyD88-Nluc and 10 ng (circle) or 50 ng (triangle) of TIRAP-Venus constructs. Cells were stimulated
with 1 μg/ml Pam3CSK4 (red and purple) or vehicle control (blue and green) and BRET measured over time. Data
shown are donor-only-subtracted BRET ratio; graphs are representative of two independent experiments. G)
HEK293FT cells were transfected with constant (100 ng) TLR1/2 and MyD88-Nluc constructs (20 ng, blue; or 10 ng,
green), and increasing (0–600 ng) TIRAP-Venus construct. Saturation curves were fitted using ‘one site—specific
binding’ function on Prism software.
https://doi.org/10.1371/journal.pone.0202408.g004
Fig 5. Immunoprecipitation does not show constitutive interactions between overexpressed TLR1/2, TIRAP and MyD88. A) HEK293FT
cells were transfected as indicated, and cell lysates were analysed by Western blotting. High and low exposure images show both Venus-tagged
(arrows) and endogenous (triangles) MyD88 and Venus in the same blot. B and C) HEK293FT cells were transfected with 100 ng of DNA
constructs as indicated. Immunoprecipitation of Venus-tagged protein was performed, and analysed by Western blot, along with input samples.
https://doi.org/10.1371/journal.pone.0202408.g005
BRET analysis of TLR-adaptor interactions is hampered by protein overexpression
PLOS ONE | https://doi.org/10.1371/journal.pone.0202408 August 23, 2018 11 / 18
Co-immunoprecipitation studies did not confirm constitutive interaction
between TLR1/2 and adaptors
In order to further investigate the constitutive interaction with TLR1/2 and TIRAP/MyD88
observed by BRET, co-immunoprecipitation (IP) was employed. Venus IP was performed on
cells expressing Venus-tagged TIRAP and untagged MyD88 (Fig 5B), or Venus-tagged MyD88
and untagged TIRAP (Fig 5C), with and without TLR1/2-Rluc8. Cells transfected with TLR1/
2-Rluc8 and untagged MyD88 and TIRAP constructs were used as a negative control (Fig 5C).
In contrast to the BRET data, the IP experiments did not demonstrate constitutive interactions
between the TLR pathway proteins.
Discussion
The downstream signalling from TLRs is hinged on interactions between receptors and adap-
tor proteins via their TIR domains [4]. Currently, there are no suitable methods available to
specifically monitor these interactions. BRET is a sensitive method for detection of specific
protein-protein interactions in live cells, and was applied to investigate the binding between
TLRs and adaptors. To our knowledge, BRET has never before been used to study TLRs, with
the closest example being the use of FRET to analyse the dimerization of TLR4 [38]. However,
BRET requires the overexpression of the proteins of interest, which can be a confounding fac-
tor if the protein activity is sensitive to expression stoichiometry. Furthermore, addition of
luciferase and fluorophore tags can, in some cases, alter the structure of the target proteins and
subsequently affect their localization or function. Therefore, the expression and subcellular
localization of tagged proteins must always be evaluated prior to application in BRET
experiments.
The BRET and confocal microscopy analysis in this study demonstrated that the
TLR2-Rluc8 and TIRAP-Venus were expressed and correctly localized at the plasma mem-
brane. However, MyD88-Venus showed intracellular localization, which has been reported
for artificially overexpressed MyD88 [9, 26, 28]. Previous work has claimed that the unique
subcellular localization of transfected MyD88 constitutes the natural distribution of the pro-
tein [28]. Yet, more recently it has been shown that endogenous MyD88 in macrophages is
found in small speckle-like formations throughout the cytoplasm, and condense into larger
structures upon TLR stimulation with ligands [39]. Thus, the observed distribution of
MyD88 when overexpressed in cells may be an artefact occurring due to the death domains
of MyD88 being prone to oligomerization. Co-expression of TIRAP and MyD88-Venus
changed the subcellular localization of MyD88-Venus to smaller speckle-like formations at
the plasma membrane, indicating that MyD88-Venus was functionally interacting with
TIRAP. The BRET experiments conducted in this study showed that, similar to the bridging
role of TIRAP in TLR4-MyD88 signalling [8, 9, 40], TIRAP is also required for MyD88 inter-
action with TLR2. Interestingly, the requirement for three-fold higher transfection amount
of TIRAP to achieve this redistribution of MyD88 indicated that there was a minimum
threshold of TIRAP required to translocate MyD88, likely by disruption of MyD88 oligomer-
ization to favour TIRAP:MyD88 complex formation. This was supported by saturation
BRET studies, which showed that the interaction between TLR1/2 and MyD88 was depen-
dent on TIRAP expression levels. This constitutes a novel concept that TIRAP expression
levels in cells could be a rate-limiting step in MyD88-dependent signalling downstream of
TLR2, and potentially of TLR4.
Ligand-induced BRET is important to show that the interactions seen between tagged
proteins are functional and biologically valid [23]. Despite several strategies used in this
study for tagging the proteins of interest, ligand-induced BRET was not observed when cells
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were treated with the TLR1/2 ligand Pam3CSK4 [3]. Saturation BRET has been extensively
used to investigate oligomerization between GPCRs [31, 33], and our experiments demon-
strated that the proteins analysed were constitutively proximal, even at low transfection con-
centrations. This was despite the use of Nluc to increase BRET sensitivity and reduce protein
expression levels [37]. Indeed, Western blot analysis showed that protein levels of ectopically
expressed TIRAP and MyD88 remained significantly higher than endogenous proteins
found in immune cells (Fig 5A). Therefore, because the tagged proteins demonstrated con-
stitutive proximity in the absence of ligand, measurement of ligand-induced BRET was not
achievable.
Most previous studies on interactions between TLRs, TIRAP and MyD88 have used protein
overexpression systems, which induced ligand-independent activation of transcription factors
such as NF-κB [6, 11, 19, 41]. Additionally, it has been reported that overexpression of TLR4
and TIRAP caused ligand-independent interactions [6]. Only recently has there been a study
demonstrating the ligand-induced interaction of endogenous MyD88 and TIRAP [34]. The
study by Bonham et al. clearly showed that MyD88 and TIRAP interacted only after stimula-
tion with TLR ligands LPS and CpG, although the authors did not investigate native interac-
tions between TLRs and TIRAP. Therefore, it is more likely that the ligand-independent
interactions between MyD88, TIRAP and TLR1/2 observed with BRET are artefacts due to the
overexpression of these proteins. This is further supported by the IP studies, which did not
show constitutive interactions between the proteins of interest. However, it is important to
note that IP studies are not without limitations, as they usually only capture strong protein-
protein interactions, whereas transient or low affinity interactions will likely not be captured
due to stringent assay conditions. Therefore, some biologically ‘real’ protein-protein interac-
tions can be lost during membrane disruption and/or under IP conditions, and thus cannot be
demonstrated with this method.
Ligand induced interactions between endogenous TLR1/2 and TIRAP have not yet been
investigated. It is possible that TLR1/2-TIRAP protein complexes could occur naturally in
cells in the absence of ligand-induction, with ligand binding causing conformational changes
in the complex that initiate the downstream signalling cascade. Another possibility is that
the proteins are located within close proximity to each other at resting state, and ligand bind-
ing rapidly induces interactions to initiate signalling. The actuality of either of these scenar-
ios remains to be determined, although it will likely not be achieved using standard BRET
techniques. Instead, to conclusively determine the native resting interactions between
these proteins, studies need to be undertaken with endogenous proteins for immunoprecipi-
tation and/or immunofluorescence studies. Alternatively, in situ knock-ins of tags using
CRISPR/Cas9 gene editing could be used to insert the luciferase and fluorophore genes,
allowing the study of TLR-MyD88-TIRAP complexes at physiological expression levels [42].
This technique has been used recently for BRET, where knock-in of Nluc overcame the need
for overexpression of donor fusion proteins [43]. However, the genomic insertion of large
genes like that of the Venus fluorophore remain a challenge, even with CRISPR/Cas9 gene
editing.
In summary, our data confirm that TIRAP is essential for MyD88 interaction with TLR1/2,
constituting a rate-limiting component of TLR1/2-MyD88 interaction. Furthermore, constitu-
tive proximity/interaction between TLR1/2 and adaptors was observed with BRET, although
this is likely to be an artefact of protein overexpression. These findings highlight the need for
caution when studying the TLR pathway through ectopic protein expression. Despite the chal-
lenges with experiments using endogenous protein expression, these are likely to be critical to
our future understanding of genuine protein-protein interactions in cells.
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Materials and methods
Constructs
Human TLR1, TLR2, and TIRAP genes were purchased from Invivogen, and all cloning was
performed by GeneArt (Life Technologies). The MyD88 gene was synthesised de novo due to
high CG content. Genes were sub-cloned into pcDNA3.1 vectors containing C-terminal
Rluc8, Nluc, or Venus tags. The Kras-Venus construct was kindly provided by Nevin Lambert.
Constructs were purified from TOP10 E. coli (Life Technologies) using an endotoxin-free
Maxiprep kit (Qiagen).
Cell culture and transfection
HEK293FT cells (Thermo Fisher Scientific) were maintained in DMEM (Dulbecco’s modified
Eagle’s medium, 4.5 g/L D-glucose, 40 mM sodium bicarbonate, 100 U/ml penicillin and
100 μg/ml streptomycin) supplemented with 10% heat-inactivated FCS, at 37˚C in a 5% CO2
humidified incubator. Cultures were maintained at sub-confluency and passaged every two to
three days using 2.5% trypsin treatment (Gibco).
HEK293FT cells were transfected using GeneJuice (Novagen) according to manufacturer’s
instructions. Briefly, 6 x 105 cells/well were added to 6-well plates 24 hr prior to transfection.
Transfection was done when cells were approximately 50% confluent, by mixing up to 1.2 μg
of expression plasmid with 100 μl of serum-free medium and 4 μl of GeneJuice. After 10 min
incubation at RT, the GeneJuice/plasmid mixture was added to cells dropwise. Cells were incu-
bated for 24–48 hr prior to assaying. The concentration of transfected DNA was always equal-
ised between samples using pcDNA3.1 empty vector.
Confocal microscopy
HEK293FT cells were transfected as described. 24 hr post-transfection, cells were detached
using trypsin treatment and 8 x 105 cells added to 6-well plates containing poly-L-lysine-coated
glass coverslips. After 24 hr, wells were washed twice with PBS prior to cell fixation using 4%
paraformaldehyde in fixative buffer (10 mM KCl, 274 mM NaCl, 8 mM NaHCO3, 0.8 mM
KH2PO4, 4 mM MgCl2, 10 mM PIPES pH 7.2, 4 mM EGTA, 11 mM glucose) for 5 min at
37˚C. Cells were permeabilised with 0.15% Triton-X 100 in fixative buffer for 20 min and
washed once with 0.1 M glycine and four times with TBS for 10 min each. Coverslips were
blocked with 1% BSA in TBS for 20 min. Coverslips were washed twice with 1% BSA in TBS
for 10 min, twice with TBS for 5 min, and mounted onto glass slides using Prolong Gold with
DAPI (Thermo Fisher). Cells were imaged on a Zeiss LS 780 confocal microscope.
Bioluminescence resonance energy transfer assays
HEK293FT cells were transfected as described, and 24 hr post-transfection cells were detached
using trypsin treatment and washed once with PBS. Cells were re-suspended at 1 x 106 cells/ml
in phenol red-free DMEM supplemented with 5% FCS and 25mM HEPES. 1 x 105 cells/well
were added to poly-L-lysine-coated opaque white 96-well plates and incubated for a further 24
hr. Medium was exchanged with medium containing 5 μM coelenterazine h and assays carried
out immediately. In some instances, 10 μl Pam3CSK4 (Pam3CysSerLys4, synthetic triacylated
lipopeptide; Invivogen) in medium was added to wells a few minutes into the assay measure-
ment, to indicated final concentrations. For NanoBRET experiments using Nluc constructs,
samples were prepared as above, but furimazine (Promega) diluted 1:500 in medium was
added to cells immediately prior to assay.
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BRET measurements at 37˚C utilised the PHERAstar plate reader and software (BMG Lab-
tech). Emissions were simultaneously measured at 400–475 nm for Rluc8 or Nluc (donor) and
at 520–540 nm for Venus (acceptor). BRET was calculated by subtracting the ratio of emission
through the acceptor wavelength window over emission through the donor wavelength win-
dow. In some instances, data were presented as BRET ratio minus donor-only control, where
donor-only control was cells transfected with luciferase-tagged DNA constructs only, to con-
trol for background luminescence.
BRET saturation assay
The BRET saturation assay was performed as described, with varying concentrations of
transfected DNA constructs, as indicated in figures. For direct fluorescence measurements,
transfected cells used in the BRET assay were also plated at 0.5 x 105 cells/well in black
96-well plates. Fluorescence after light excitation was measured on an EnVision 2102 plate
reader (PerkinElmer Life Sciences) using a 485/14 excitation filter, 535/25 emission filter,
and D505 mirror. Luminescence data points were selected at time points when maximal
luminescence was obtained. BRET ratios at that same time point were used. Data were plot-
ted as BRET ratio vs. fluorescence/luminescence, and curves were fitted using ‘one site—
specific binding’ function on Prism software (GraphPad). BRET50, corresponding to the
fluorescence/luminescence value at 50% of the maximum BRET ratio, was calculated as the
equilibrium dissociation constant (Kd) from the fitted curve. In order to determine if the
relationship was linear or saturated, all curves were compared to a ‘line through origin’ curve
(null hypothesis indicating a linear relationship), and the null hypothesis was rejected if the
p-value was less than 0.05.
Western blotting and immunoprecipitation
HEK293FT cells transfected as for BRET assay, THP1 cells, or human primary monocyte-
derived dendritic cells were lysed as described previously [44]. Protein concentrations were
determined using the Pierce BCA Protein Assay Kit (Thermo Fisher) and equalized between
samples. For Venus immunoprecipitation, Venus cross-reacting GFP-Trap beads (Chromo-
tek) were used according to manufacturer’s instructions. Samples and Novex Sharp protein
size marker (Thermo Fisher) were separated by SDS-PAGE using the NuPAGE system with
4–12% Bis-Tris gels (Thermo Fisher) and transferred onto nitrocellulose membranes using the
Criterion transfer system (Bio-Rad). Membranes were probed with antibodies against TLR1
(Cell Signalling Technology), TLR2 (D7G9Z, Cell Signalling Technology), MyD88 (D80F5,
Cell Signalling Technology), TIRAP (EPR3509, Abcam), GFP (cross-reacts with Venus, 13.1/
7.1, Roche), or Renilla luciferase (EPR17791, Abcam), followed by secondary probing with
HRP-conjugated anti-mouse or anti-rabbit antibodies (GE Healthcare) as previously described
[44]. HRP-conjugated antibodies against β-actin (AC-15, Sigma) and GAPDH (Proteintech)
were used to demonstrate even lane loading.
TNF ELISA
HEK293FT cells transfected as for BRET assay, or THP1 cells were plated in 96-well plates as
described above. After 24 hr, cells were treated with vehicle or Pam3CSK4 as indicated and
incubated for a further 24 hr. Subsequently, cell culture supernatant was collected and TNF
ELISA (Invitrogen eBioscience Human TNF alpha ELISA Ready-SET-Go! Kit) performed
according to manufacturer’s instructions.
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NF-κB luciferase
HEK293FT cells were transfected as for BRET assays, and additionally with NF-κB Firefly
luciferase reporter DNA construct as indicated. After 48 hr, cells were lysed using Passive Lysis
Buffer (Promega), and Renilla and Firefly luciferase activity were measured sequentially using
the Dual-Glo Luciferase Assay System (Promega) on a GloMax luminometer (Promega),
according to manufacturer’s instructions.
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